VBLT - Vascular Biogenics Ltd.
| Previous Close | 2.75 |
| Open | 2.75 |
| Bid | 2.60 x 1400 |
| Ask | 2.65 x 3000 |
| Day's Range | 2.60 - 2.77 |
| 52 Week Range | 2.01 - 9.05 |
| Volume | 92,395 |
| Avg. Volume | 243,593 |
| Market Cap | 78.331M |
| Beta | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.44 |
| Earnings Date | Aug 13, 2018 - Aug 17, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- ACCESSWIRE•yesterday
Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks
LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Ahead of today's trading session, WallStEquities.com observes Teligent Inc. (NASDAQ: TLGT), Tesaro Inc. (NASDAQ: TSRO), Vascular Biogenics Ltd (NASDAQ: VBLT), and VistaGen Therapeutics Inc. (NASDAQ: VTGN).
- ACCESSWIRE•14 days ago
Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday's trading session. Enanta climbed higher ...
- Benzinga•15 days ago
Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 5) Haemonetics Corporation (NYSE: HAE ) Athersys, Inc. (NASDAQ: ...
- GlobeNewswire•16 days ago
VBL Therapeutics Presents Positive Data on its MOSPD2 Platform Technology in Oncology and Inflammation at BIO 2018
"Our research has shown that MOSPD2 plays a key role in the regulation of cell motility,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. "We have generated data indicating that MOSPD2 is required for directional movement, or chemotaxis, of tumor cells and certain immune cells, and therefore appears to play a central role in both oncology and inflammation.
- GlobeNewswire•28 days ago
VBL Therapeutics to Present at Upcoming Conferences in June
TEL AVIV, Israel, May 24, 2018-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of VBLT earnings conference call or presentation 17-May-18 12:30pm GMT
Q1 2018 Vascular Biogenics Ltd Earnings Call
- Associated Press•last month
Vascular Biogenics: 1Q Earnings Snapshot
On a per-share basis, the Or Yehuda, Israel-based company said it had a loss of 24 cents. The gene therapy biotech company posted revenue of $163,000 in the period. The company's shares closed at $2.23. ...
- GlobeNewswire•last month
VBL Therapeutics Announces First Quarter 2018 Financial Results
Conference Call and Webcast at 8:30am Eastern Time Today. TEL AVIV, Israel, May 17, 2018-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization ...
- ACCESSWIRE•last month
Vascular Biogenics Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Vascular Biogenics Ltd. (NASDAQ: VBLT ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 17, 2018 at 8:30 AM Eastern Time. ...
- GlobeNewswire•last month
VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15
VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will present data on its novel MOSPD2 program at the 17th MIXiii-BIOMED 2018 Conference and Exhibition, to be held May 15-17, 2018 in Tel Aviv, Israel. MOSPD2 is a novel tumor-related target identified by VBL that may be used as a marker for selective targeting of several types of tumors. Research conducted by VBL has shown that MOSPD2 is a novel membrane protein found on tumor cells that is present when they start invading tissues or creating metastatic lesions. The Company believes that targeting of MOSPD2 may have several therapeutic applications, including inhibition of tumor cell metastases and targeting of MOSPD2-positive tumor cells.
- GlobeNewswire•2 months ago
VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17
TEL AVIV, Israel, May 01, 2018-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...
- Zacks•2 months ago
Vascular Biogenics (VBLT) Enters Oversold Territory
Vascular Biogenics Ltd. (VBLT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
- GlobeNewswire•2 months ago
VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR
TEL AVIV, Israel, April 16, 2018-- VBL Therapeutics today presented a late-breaking study demonstrating a novel bi-specific antibody that induces immune-cell mediated killing of cancer cells through binding ...
- Zacks•2 months ago
Implied Volatility Surging for Vascular Biogenics (VBLT) Stock Options
Surging implied volatility makes Vascular Biogenics (VBLT) stock lucrative to the option traders.
- GlobeNewswire•2 months ago
VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16
TEL AVIV, Israel, April 10, 2018-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...
- GlobeNewswire•2 months ago
VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority
TEL AVIV, Israel, April 09, 2018-- VBL Therapeutics today announced that it has been awarded a grant of 8.9 million New Israeli Shekels by the Israel Innovation Authority. The funds will support the development ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of VBLT earnings conference call or presentation 15-Mar-18 12:30pm GMT
Q4 2017 Vascular Biogenics Ltd Earnings Call
- ACCESSWIRE•3 months ago
Vascular Biogenics Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Vascular Biogenics Ltd. (NASDAQ: VBLT ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 8:30 AM Eastern ...
- Simply Wall St.•5 months ago
Does Vascular Biogenics Ltd’s (NASDAQ:VBLT) CEO Pay Compared Well With Peers?
Dror Harats is the CEO of Vascular Biogenics Ltd (NASDAQ:VBLT), which has recently grown to a market capitalization of $222.93M. Understanding how CEOs are incentivised to run and grow theirRead More...
- Simply Wall St.•6 months ago
Vascular Biogenics Ltd (NASDAQ:VBLT): Is Healthcare An Attractive Sector Play?
Vascular Biogenics Ltd (NASDAQ:VBLT), a USD$223.68M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
